LLukas22/scidocs huggingface dataset:
Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial.

PURPOSE
We hypothesized that high-dose stereotactic body radiation therapy (SBRT) would lead to faster time to nadir and lower nadir values compared with conventional radiation therapy experiences. We now report prostate-specific antigen (PSA) kinetics following high-dose SBRT in patients treated with radiation alone.


METHODS AND MATERIALS
Ninety-one patients were enrolled on the phase 1/2 dose escalation study of SBRT for localized prostate cancer. All patients with at least 36 months of follow-up and without hormone therapy were included in this analysis (n = 47). Treatment response parameters evaluated include time to nadir, nadir value, occurrence of PSA bounces (rise of ≥0.2 ng/mL followed by a subsequent fall), magnitude of bounces, duration of bounces, and correlation of bounces with clinical outcomes.


RESULTS
Median follow-up was 42 months (range, 36-78 months). Treatment dose levels were 45 Gy (n = 10), 47.5 Gy (n = 8), and 50 Gy (n = 29) in 5 fractions. Biochemical control rate was 98%. Median PSA at follow-up was 0.10 ± 0.20 ng/mL. Median time to nadir was 36 ± 11 months. A total of 24/47 (51.1%) patients had ≥1 PSA bounce. Median magnitude of PSA rise during bounce was 0.50 ± 1.2 ng/mL. Median time to first bounce was 9 ± 7.0 months. Median bounce duration was 3 ± 2.3 months for the first bounce and 6 ± 5.2 months for subsequent bounces. Prostate volumes <30 mL were associated with a decreased likelihood of bounce (P = .0202), and increasing prostate volume correlated with increasingly likelihood of having ≥2 bounces (P = .027). Patients reaching PSA nadir of ≤0.1 ng/mL were less likely to experience any bounce (P = .0044).


CONCLUSIONS
Compared with other SBRT experiences, our study demonstrated a higher PSA bounce rate, a similar or shorter median time to bounce, and a very low nadir. Prostate volume appears correlated with bounce.
Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin.

BACKGROUND
Proinflammatory cytokines released by injured endothelium facilitate interaction of endothelial cells with circulating leukocytes and thus may contribute to development and progression of atherosclerosis. We investigated whether cytokines and C-reactive protein (CRP) are indicative of myocardial ischemia or of diseased vessels and whether they are influenced by aspirin treatment in patients with chronic stable angina.


METHODS AND RESULTS
Plasma macrophage colony stimulating factor (MCSF), IL-1b, IL-6, and CRP were measured in 60 stable patients after 48-hour Holter monitoring and in 24 matched controls. All patients had angiographic documentation of disease and positive exercise ECGs. Patients with ischemia on Holter monitoring (n=40) received aspirin or placebo in a 6-week, randomized, double blind, crossover trial. Blood sampling was repeated at the end of each treatment phase (3 weeks). Compared to controls, patients had more than twice median MCSF (800 versus 372 pg/mL), IL-6 (3.9 versus 1.7 pg/mL), and CRP (1.25 versus 0.23 mg/L) levels (P<0.01 for all comparisons). MCSF was related to ischemia on Holter monitoring (P<0.01), to low ischemic threshold during exercise (P<0.01), and together with IL-1b to number of diseased vessels (P<0.05). MCSF, IL-6, and CRP were all reduced after 6 weeks of aspirin treatment (P<0.05).


CONCLUSIONS
These findings suggest that cytokines are associated with both ischemia and anatomic extent of disease in patients with stable angina. Reduced cytokine and CRP levels by aspirin may explain part of aspirin's therapeutic action.
Time and sample efficient discovery of Markov blankets and direct causal relations

Data Mining with Bayesian Network learning has two important characteristics: under conditions learned edges between variables correspond to casual influences, and second, for every variable T in the network a special subset (Markov Blanket) identifiable by the network is the minimal variable set required to predict T. However, all known algorithms learning a complete BN do not scale up beyond a few hundred variables. On the other hand, all known sound algorithms learning a local region of the network require an exponential number of training instances to the size of the learned region.The contribution of this paper is two-fold. We introduce a novel local algorithm that returns all variables with direct edges to and from a target variable T as well as a local algorithm that returns the Markov Blanket of T. Both algorithms (i) are sound, (ii) can be run efficiently in datasets with thousands of variables, and (iii) significantly outperform in terms of approximating the true neighborhood previous state-of-the-art algorithms using only a fraction of the training size required by the existing methods. A fundamental difference between our approach and existing ones is that the required sample depends on the generating graph connectivity and not the size of the local region; this yields up to exponential savings in sample relative to previously known algorithms. The results presented here are promising not only for discovery of local causal structure, and variable selection for classification, but also for the induction of complete BNs.
Concatenation of Hamming Codes and Accumulator Codes with High-Order Modulations for High-Speed Decoding

We propose a concatenated code structure combined with high-order modulations suitable for implementation with iterative decoders operating at gigabit-persecond (Gbps) data rates. The examples considered in this article are serial/parallel concatenations of Hamming and accumulator codes. Performance results are given for binary phase-shift keyed (BPSK) modulation, quadrature phase-shift keyed (QPSK) modulation, 8 phase-shift keyed (8PSK) modulation, and 16 quadrature amplitude modulation (16QAM) over additive white Gaussian noise (AWGN) and Rayleigh fading channels.
Alzheimer's disease - input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial

BACKGROUND
Current treatments for Alzheimer's disease and related disorders (ADRD) are symptomatic and can only temporarily slow down ADRD. Future possibilities of care rely on multi-target drugs therapies that address simultaneously several pathophysiological processes leading to neurodegeneration. We hypothesized that the combination of memantine with vitamin D could be neuroprotective in ADRD, thereby limiting neuronal loss and cognitive decline. The aim of this trial is to compare the effect after 24 weeks of the oral intake of vitamin D3 (cholecalciferol) with the effect of a placebo on the change of cognitive performance in patients suffering from moderate ADRD and receiving memantine.


METHODS
The AD-IDEA Trial is a unicentre, double-blind, randomized, placebo-controlled, intent-to-treat, superiority trial. Patients aged 60 years and older presenting with moderate ADRD (i.e., Mini-Mental State Examination [MMSE] score between 10-20), hypovitaminosis D (i.e., serum 25-hydroxyvitamin D [25OHD] < 30 ng/mL), normocalcemia (i.e., serum calcium < 2.65 mmol/L) and receiving no antidementia treatment at time of inclusion are being recruited. All participants receive memantine 20 mg once daily -titrated in 5 mg increments over 4 weeks- and each one is randomized to one of the two treatment options: either cholecalciferol (one 100,000 IU drinking vial every 4 weeks) or placebo (administered at the same pace). One hundred and twenty participants are being recruited and treatment continues for 24 weeks. Primary outcome measure is change in cognitive performance using Alzheimer's Disease Assessment Scale-cognition score. Secondary outcomes are changes in other cognitive scores (MMSE, Frontal Assessment Battery, Trail Making Test parts A and B), change in functional performance (Activities of Daily Living scale, and 4-item Instrumental Activities of Daily Living scale), posture and gait (Timed Up & Go, Five Time Sit-to-Stand, spatio-temporal analysis of walking), as well as the between-groups comparison of compliance to treatment and tolerance. These outcomes are assessed at baseline, 12 and 24 weeks, together with the serum concentrations of 25OHD, calcium and parathyroid hormone.


DISCUSSION
The combination of memantine plus vitamin D may represent a new multi-target therapeutic class for the treatment of ADRD. The AD-IDEA Trial seeks to provide evidence on its efficacy in limiting cognitive and functional declines in ADRD.


TRIAL REGISTRATION
ClinicalTrials.gov number, NCT01409694.
Digital Wildfires: Propagation, Verification, Regulation, and Responsible Innovation

Social media platforms provide an increasingly popular means for individuals to share content online. Whilst this produces undoubted societal benefits, the ability for content to be spontaneously posted and reposted creates an ideal environment for rumour and false/malicious information to spread rapidly. When this occurs it can cause significant harm and can be characterised as a “digital wildfire.” In this article, we demonstrate that the propagation and regulation of digital wildfires form important topics for research and conduct an overview of existing work in this area. We outline the relevance of a range of work from the computational and social sciences, including a series of insights into the propagation of rumour and false/malicious information. We argue that significant research gaps remain—for instance, there is an absence of systematic studies on the effects of digital wildfires and there is a need to combine empirical research with a consideration of how the responsible governance of social media can be determined. We propose an agenda for research that establishes a methodology to explore in full the propagation and regulation of unverified content on social media. This agenda promotes high-quality interdisciplinary research that will also inform policy debates.
The influence of g.19124G>a genetic polymorphism in the OPG gene on bone mineral density in Chinese women.

OBJECTIVE
The aim of this study was to detect the influence of g.19124G>A genetic polymorphism in the osteoprotegerin (OPG) gene on bone mineral density (BMD) and osteoporosis in Chinese postmenopausal women.


METHODS
A total of 403 primary osteoporosis subjects and 409 healthy controls were enrolled in this study. The BMD value of the femoral neck hip, lumbar spine (L(2-4)), and total hip was analyzed by Norland XR-46 dual energy X-ray absorptiometry. The polymerase chain reaction-restriction fragment length polymorphism method was utilized to investigate the genotype of g.19124G>A genetic polymorphism.


RESULTS
We found significant differences of the femoral neck hip, lumbar spine (L(2-4)), and total hip of BMD among different genotypes of g.19124G>A genetic polymorphism, individuals with the genotype GG had significantly higher BMD than those of genotype GA and AA (p<0.05).


CONCLUSION
These findings indicate that the g.19124G>A genetic polymorphism in the OPG gene is potentially related to BMD and osteoporosis in Chinese postmenopausal women, and the allele A could be associated with a lower BMD and an increased risk factor for osteoporosis.
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

PURPOSE
Four US National Clinical Trials Network components (Southwest Oncology Group, Cancer and Leukemia Group B/Alliance, Eastern Cooperative Oncology Group, and the AIDS Malignancy Consortium) conducted a phase II Intergroup clinical trial that used early interim fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to determine the utility of response-adapted therapy for stage III to IV classic Hodgkin lymphoma.


PATIENTS AND METHODS
The Southwest Oncology Group S0816 (Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma) trial enrolled 358 HIV-negative patients between July 1, 2009, and December 2, 2012. A PET scan was performed after two initial cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and was labeled PET2. PET2-negative patients (Deauville score 1 to 3) received an additional four cycles of ABVD, whereas PET2-positive patients (Deauville score 4 to 5) were switched to escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for six cycles. Among 336 eligible and evaluable patients, the median age was 32 years (range, 18 to 60 years), with 52% stage III, 48% stage IV, 49% International Prognostic Score 0 to 2, and 51% score 3 to 7.


RESULTS
Three hundred thirty-six of the enrolled patients were evaluable. Central review of the interim PET2 scan was performed in 331 evaluable patients, with 271 (82%) PET2-negative and 60 (18%) PET2-positive. Of 60 eligible PET2-positive patients, 49 switched to eBEACOPP as planned and 11 declined. With a median follow-up of 39.7 months, the Kaplan-Meier estimate for 2-year overall survival was 98% (95% CI, 95% to 99%), and the 2-year estimate for progression-free survival (PFS) was 79% (95% CI, 74% to 83%). The 2-year estimate for PFS in the subset of patients who were PET2-positive after two cycles of ABVD was 64% (95% CI, 50% to 75%). Both nonhematologic and hematologic toxicities were greater in the eBEACOPP arm than in the continued ABVD arm.


CONCLUSION
Response-adapted therapy based on interim PET imaging after two cycles of ABVD seems promising with a 2-year PFS of 64% for PET2-positive patients, which is much higher than the expected 2-year PFS of 15% to 30%.
An Analysis of BGP Convergence Properties

The Border Gateway Protocol (BGP) is the de facto inter-domain routing protocol used to exchange reachability information between Autonomous Systems in the global Internet. BGP is a path-vector protocol that allows each Autonomous System to override distance-based metrics with policy-based metrics when choosing best routes. Varadhan et al. [18] have shown that it is possible for a group of Autonomous Systems to independently define BGP policies that together lead to BGP protocol oscillations that never converge on a stable routing. One approach to addressing this problem is based on static analysis of routing policies to determine if they are safe. We explore the worst-case complexity for convergence-oriented static analysis of BGP routing policies. We present an abstract model of BGP and use it to define several global sanity conditions on routing policies that are related to BGP convergence/divergence. For each condition we show that the complexity of statically checking it is either NP-complete or NP-hard.
Nanoparticle-based combination drug delivery systems for synergistic cancer treatment

Despite being a leading cause of death worldwide, cancer remains difficult to treat due to the development of drug resistance and severe adverse effects associated with conventional chemotherapy. Hence, combination chemotherapy is theoretically advantageous owing to the synergistic effects of drugs and suppression of drug resistance. Nanoparticle-mediated chemotherapeutic delivery is a promising approach for the effective treatment of various cancers because it may simultaneously enhance therapeutic effects and reduce side effects. The loading of multiple chemotherapeutic agents to these systems could additionally improve the antineoplastic efficacy. This review highlights recent advances in combination chemotherapy using small-molecule chemotherapeutic agents via nanocarrier systems, e.g., liposomes, polymeric micelles, dendrimers, polymer-drug conjugates, and mesoporous silica nanoparticles. Specifically, it emphasizes the unique properties of these systems that make them amenable to optimized treatments with respect to efficacy and safety and clarifies areas in which current therapeutic strategies can be improved.
UAV PHOTOGRAMMETRY FOR MAPPING AND 3 D MODELING – CURRENT STATUS AND FUTURE PERSPECTIVES –

UAV platforms are nowadays a valuable source of data for inspection, surveillance, mapping and 3D modeling issues. New applications in the shortand close-range domain are introduced, being the UAVs a low-cost alternatives to the classical manned aerial photogrammetry. Rotary or fixed wing UAVs, capable of performing the photogrammetric data acquisition with amateur or SLR digital cameras, can fly in manual, semi-automated and autonomous modes. With a typical photogrammetric pipeline, 3D results like DSM/DTM, contour lines, textured 3D models, vector data, etc. can be produced, in a reasonable automated way. The paper reports the latest developments of UAV image processing methods for photogrammetric applications, mapping and 3D modeling issues. Automation is nowadays necessary and feasible at the image orientation, DSM generation and orthophoto production stages, while accurate feature extraction is still an interactive procedure. New perspectives are also addressed. Figure 1: Example of scenes surveyed with a UAV system (Microdrone MD4-200) and photogrammetric results achieved from the acquired images: digital surface model, orthoimages and overlaid contours (archaeological area in Montalcino, Italy).
Quantum complexity theory

In this paper we study quantum computation from a complexity theoretic viewpoint. Our first result is the existence of an efficient universal quantum Turing machine in Deutsch’s model of a quantum Turing machine (QTM) [Proc. Roy. Soc. London Ser. A, 400 (1985), pp. 97–117]. This construction is substantially more complicated than the corresponding construction for classical Turing machines (TMs); in fact, even simple primitives such as looping, branching, and composition are not straightforward in the context of quantum Turing machines. We establish how these familiar primitives can be implemented and introduce some new, purely quantum mechanical primitives, such as changing the computational basis and carrying out an arbitrary unitary transformation of polynomially bounded dimension. We also consider the precision to which the transition amplitudes of a quantum Turing machine need to be specified. We prove that O(log T ) bits of precision suffice to support a T step computation. This justifies the claim that the quantum Turing machine model should be regarded as a discrete model of computation and not an analog one. We give the first formal evidence that quantum Turing machines violate the modern (complexity theoretic) formulation of the Church–Turing thesis. We show the existence of a problem, relative to an oracle, that can be solved in polynomial time on a quantum Turing machine, but requires superpolynomial time on a bounded-error probabilistic Turing machine, and thus not in the class BPP. The class BQP of languages that are efficiently decidable (with small error-probability) on a quantum Turing machine satisfies BPP ⊆ BQP ⊆ P. Therefore, there is no possibility of giving a mathematical proof that quantum Turing machines are more powerful than classical probabilistic Turing machines (in the unrelativized setting) unless there is a major breakthrough in complexity theory.
CiteVis : Exploring Conference Paper Citation Data Visually

Citation counts and intra-conference citations are one useful measure of the impact of prior research in a field. We have developed CiteVis, a visualization system for portraying citation data about the IEEE InfoVis Conference and its papers. Rather than use a node-link network visualization, we employ an attribute-based layout along with interaction to foster exploration and knowledge discovery.
Osteopathy for primary headache patients: a systematic review

OBJECTIVE
This systematic review aimed to assess the efficacy, effectiveness, safety, and tolerability of osteopathic manipulative treatment (OMT) in patients with headache.


BACKGROUND
Migraine is one of the most common and disabling medical conditions. It affects more than 15% of the general population, causing high global socioeconomic costs, and the currently available treatment options are inadequate.


METHODS
We systematically reviewed all available studies investigating the use of OMT in patients with migraine and other forms of headache.


RESULTS
The search of literature produced six studies, five of which were eligible for review. The reviewed papers collectively support the notion that patients with migraine can benefit from OMT. OMT could most likely reduce the number of episodes per month as well as drug use. None of the included studies, however, was classified as low risk of bias according to the Cochrane Collaboration's tool for assessing risk of bias.


CONCLUSION
The results from this systematic review show a preliminary low level of evidence that OMT is effective in the management of headache. However, studies with more rigorous designs and methodology are needed to strengthen this evidence. Moreover, this review suggests that new manual interventions for the treatment of acute migraine are available and developing.
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

Acute myeloid leukemia (AML) is a disease of the elderly. Poor outcomes with standard therapies necessitate novel approaches. Outpatient regimens sufficiently potent and well tolerated to induce remissions and enable continuation therapy may be beneficial. In this phase-1 study, we determined the maximum tolerated dose (MTD) and the efficacy for sequential azacitidine and lenalidomide as remission induction and continuation therapy in elderly, previously untreated patients. We investigated the impact on global DNA methylation and bone marrow cytokines, and sought biological predictors of response. Eighteen patients were enrolled. The MTD was not reached. Median follow-up was 8.2 months (10.3 months for survivors). Common adverse events included fatigue, injection site reactions, constipation, nausea, pruritus and febrile neutropenia. Ten patients responded (56%), and the rate of complete remissions (CRs) or CRs with incomplete recovery of blood counts for evaluable patients was 44% (7/16). The median response duration was 6.2 months. DNA demethylation and changes in bone marrow cytokines were observed; responders had a unique cytokine profile and a trend towards lower methylation levels. Sequential azacitidine and lenalidomide was well tolerated with encouraging clinical and biological activity in previously untreated elderly AML patients. This trial is registered at ClinicalTrials.gov (NCT00890929).